Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Polycystic Ovary Syndrome 3Peripheral Nervous System Diseases 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Stomatitis 2Stomach Neoplasms 2Pseudomyxoma Peritonei 2Ototoxicity 2Neurofibromatosis 1 2Neoplasms 2Liver Neoplasms 2Hearing Loss 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Weight Loss 1Ulcer 1Tongue Neoplasms 1Tomaculous neuropathy 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Renal Insufficiency, Chronic 1Renal Artery Obstruction 1Radiation-Induced Mucositis 1Radiation Pneumonitis 1Pulmonary Embolism 1Primary Myelofibrosis 1Primary Graft Dysfunction 1

Interventions

Filgrastim 13Temozolomide 9Carboplatin 8Peripheral Blood Stem Cell Transplantation 6Etoposide 5Cyclophosphamide 5sargramostim 4Magnetic Resonance Spectroscopy 4Irinotecan 4Erlotinib Hydrochloride 4Topotecan 3Thiotepa 3Radiotherapy 3Oxaliplatin 3O(6)-benzylguanine 3Granulocyte Colony-Stimulating Factor 3Busulfan 3etoposide phosphate 2Vorinostat 2Vincristine 2Specimen Handling 2Psychiatric Rehabilitation 2Melphalan 2Ifosfamide 2Everolimus 2Cyproheptadine 2Cisplatin 2Carmustine 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Familial ependymoma × Acetylcysteine × Clear all
NCT00238173 2017-04-21

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
CNS

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Optic Nerve Glioma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡